生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research. Scriptaid (1 µg/mL) treatment inhibits cell growth in breast cancer cell lines, results in increased accumulation of both acetyl H3 and acetyl H4 proteins in MDA-MB-231, MDA-MB-435, and Hs578t cells. Scriptaid also inhibits cell growth of MDA-MB-231, MDA-MB-435, and Hs578t cell lines, with IC50s of 0.5-1.0 µg/mL. Scriptaid (0.1-1.0 µg/mL) induces ER and PR mRNA expression in a dose dependent manner; when it is combined with AZA(5-aza-2'-deoxycytidine), they enhance ER expression and induce a functional ER protein (estrogen receptor alpha)[3]. Scriptaid and SAHA (suberoylanilide hydroxamic acid) preferentially inhibit the Class I histone deacetylases, hdac1, 2, and 3. Scriptaid is a potent anti-T. gondii compound with low cytotoxicity, and the IC50 is 39 nM. Scriptaid has atypical effects in T. gondiiinfected HS68 cells[4]. Scriptaid inhibited the growth of HeLa cells with IC50 of 2μM at 48h in a dose-dependent manner[5]. Treatment with 500nM scriptaid caused a significant increase in the acetylation of H3K9, H3K14, and H4K5. cEFs treated with 500nM. Scriptaid showed significantly decreased Gcn5, Hat1, Hdac6, and Bcl2 and increased Oct4 and Sox2 expression levels. Scriptaid affected the reprogramming of canine donor and cloned embryos, as well as early embryo development in canine-porcine iSCNT, by regulating reprogramming and apoptotic genes[6]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.06mL 0.61mL 0.31mL |
15.32mL 3.06mL 1.53mL |
30.64mL 6.13mL 3.06mL |
参考文献 |
---|